Treatment of Relapsed Acute Lymphoblastic Leukemia

摘要: Acute lymphoblastic leukemia (ALL) is the most frequent malignant disease in childhood. With currently used treatment, event-free survival rates (EFS) range from 70 to 75%. However, relapse of ALL remains fourth diagnosis childhood cancer, with an incidence ranging close that neuroblastoma (1,2). Compared prognosis for newly diagnosed ALL, chance long-term substantially reduced cases relapse. The remission rate limited by a higher induction deaths owing tolerance treatment after organ-toxic frontline therapy. Furthermore, nonresponses increased, since blast cells surviving intensive front line have had develop resistance toward commonly antileukemic drugs. Even if complete (CR) can be achieved, subsequent relapses high.